ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2600

Clinically Meaningful Improvement in Health-Related Quality of Life and the Association with Disease Activity in Psoriatic Arthritis after Treatment with Guselkumab: Results from a Randomized Placebo-Controlled Phase II Clinical Trial

Laure Gossec1, Bruce Kirkham2, Proton Rahman3, Philip Helliwell4, Alice B Gottlieb5, Wolf-Henning Boehncke6 and Chenglong Han7, 1Rheumatology Department, Hôpital Pitié Salpêtrière, Paris 06 University, Paris, France, 2Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, 3Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, 4LIMM, Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, 5Department of Dermatology, New York Medical College, Metropolitan Hospital, New York, NY, 6Department of Dermatology and Venereology, Geneva University Hospital, Geneva, Switzerland, 7Janssen Global Services, LLC, Malvern, PA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Disease Activity, psoriatic arthritis and quality of life

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: To evaluate the effect of guselkumab (GUS) on Health-Related Quality of Life (HRQOL) and correlate changes of HRQOL and disease activity in patients with psoriatic arthritis (PsA).

Methods: Patients from the Phase 2a, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of guselkumab in the treatment of patients with active PsA were analyzed. Patients with active PsA and ≥3% body surface area (BSA) of plaque psoriasis despite current or previous treatment with standard-of-care therapies, including those previously exposed to anti-TNFα agents, were randomized 2:1 to receive GUS 100mg subcutaneously or placebo (PBO) at wks0, 4, and every 8wks (q8w) thereafter through wk44. At wk16, pts from either group with <5% improvement from baseline in both swollen and tender joint counts were eligible for early escape to open-label ustekinumab. At wk24, all remaining PBO pts crossed-over to receive GUS 100 mg, and then received GUS at wk28, and q8w thereafter through wk44. HRQOL was assessed using 36-Item Short Form Health Survey (SF-36) which assesses general health from 8 functional areas. A physical and mental component summary scores (PCS and MCS) were derived from 8 scale scores. A change of ≥5 points from the baseline in PCS or MCS was defined as clinically meaningful. Correlations of changes in SF-36 PCS and MCS with changes in Disease Activity in Psoriatic Arthritis (DAPSA) were evaluated using Spearman correlation at Week 24.

Results: The mean (SD) of SF-36 PCS and MCS at the baseline was 33.8 (7.4), 44.2 (11.9), respectively, which were significant below the US population norm (50 +/-10). At wk24, patients in the GUS group achieved statistically greater mean improvement in SF-36 PCS (6.6) and MCS (4.7) than PBO group (0.5 in PCS, -0.1 in MCS) (all p<0.01); and greater proportions of patients in GUS group achieved a clinically meaningful improvement in PCS (55%) and MCS (47%) than patients in PBO group (22.5% in PCS, p<0.001; 26.5% in MCS, p=0.017). Additionally, greater mean improvements in all SF-36 scales score in GUS group than PBO group were observed. At wk44, patients randomized to PBO at the baseline and crossed over to GUS at wk24 achieved improvements in SF-36 PCS (8.0) or MCS (5.5). The magnitude of these changes was similar to patients randomized to GUS at baseline (8.3 in PCS, 5.6 in MCS). Change in DAPSA score at wk24 was significantly correlated with change in PCS (r=-0.57, p<0.001) and MCS (r=-0.45, p<0.001).

Conclusion: GUS-treated PsA patients demonstrated significant improvement in HRQOL and in all subscales of SF-36, indicating patient-perceived improvements in health status. Improvement in SF-36 was highly correlated with reduction in PsA disease activity.


Disclosure: L. Gossec, Janssen Research Development, LLC, 2; B. Kirkham, Janssen Research Development, LLC, 2; P. Rahman, Janssen Research Development, LLC, 2; P. Helliwell, Janssen Research & Development, LLC., 2; A. B. Gottlieb, Janssen Research & Development, LLC., 2; W. H. Boehncke, Janssen Research & Development, LLC, 2; C. Han, Janssen Research & Development, LLC, 3.

To cite this abstract in AMA style:

Gossec L, Kirkham B, Rahman P, Helliwell P, Gottlieb AB, Boehncke WH, Han C. Clinically Meaningful Improvement in Health-Related Quality of Life and the Association with Disease Activity in Psoriatic Arthritis after Treatment with Guselkumab: Results from a Randomized Placebo-Controlled Phase II Clinical Trial [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/clinically-meaningful-improvement-in-health-related-quality-of-life-and-the-association-with-disease-activity-in-psoriatic-arthritis-after-treatment-with-guselkumab-results-from-a-randomized-placebo/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinically-meaningful-improvement-in-health-related-quality-of-life-and-the-association-with-disease-activity-in-psoriatic-arthritis-after-treatment-with-guselkumab-results-from-a-randomized-placebo/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology